Glycorex Reports Q2 2025 Revenue Growth Amid Sustained Losses
Glycorex announces Q2 2025 revenue growth despite ongoing operating losses.
Key Points
- • Glycorex's Q2 2025 operating loss improves to -1.0 million SEK from -2.0 million SEK in Q2 2024.
- • Revenue grows 11% to 10.2 million SEK, highlighting strong performance in Germany and Mexico.
- • Cash flow from operations improves to -0.7 million SEK, compared to -1.9 million SEK last year.
- • Liquid assets rise to 11.4 million SEK, up from 6.9 million SEK a year earlier.
Glycorex, a company focused on transplantation solutions, has released its Q2 2025 financial results, showcasing a notable increase in revenue despite continuing operational losses. The company reported an operating result of -1.0 million SEK, an improvement from -2.0 million SEK in the same quarter last year. Revenue rose by 11% to 10.2 million SEK compared to 9.1 million SEK, primarily fueled by robust growth in its key market of Germany, as well as in Mexico.
Additionally, cash flow from operations improved to -0.7 million SEK from -1.9 million SEK in Q2 2024, indicating a positive trend despite ongoing financial challenges. At the closing of the reporting period, Glycorex boasted liquid assets of 11.4 million SEK, significantly up from 6.9 million SEK a year earlier. CEO Johan Nilsson remarked on the company's meaningful progress aligned with its growth strategy, emphasizing the solid performance in Germany as a vital component of their success.
Overall, while the company continues to navigate operating losses, the encouraging revenue growth and improved cash flow signal a potential turnaround in its financial trajectory.